Clinical Trials Logo
  1. Home
  2. Acute Myeloid Leukemia, Adult
  3. NCT04752527

Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features

Acute Myeloid Leukemia, Adult Clinical Trial

Official title:
The Clinical Study of Individualized Induction Therapy for Non-elderly Patients With Acute Myeloid Leukemia and Adverse Risk Features Guided by Rapid Screening With FISH and NGS

Clinical Trial Summary

Individualized induction therapy will be applied to the non-elderly acute myeloid leukemia (AML) patients with adverse genetic risk features guided by rapid screening with fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS), such as the combination of Venetoclax plus decitabine, and Sorafenib for patients with high (FMS)-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) allelic ratio. This study aims to improve induction therapy for non-elderly AML patients with adverse genetic risk features, reduce treatment-related complications, and improve overall survival.

Clinical Trial Description

The non-elderly AML patients who meet the adverse risk group defined as 2017 European LeukemiaNet (ELN) risk stratification, are more likely to be refractory to intensive induction and have low rates of long-term survival. Venetoclax (drug name) plus decitabine or azacitidine showed tolerable safety and favorable overall response rate (ORR )(complete remission (CR)+CR with incomplete hematologic recovery (CRi) rate: 67%) in elderly AML patients. In addition, combination therapy with sorafenib, cytarabine and idarubicin was able to induce a high CR rate in non-elderly AML patients with FLT3 mutations and a 1-year probability of survival of 74%. The fast next-generation sequencing together with FISH can identify the adverse genetic risk features in AML patients within 72 hours. Individualized induction therapy will be applied to the non-elderly AML patients with adverse genetic risk features guided by rapid screening with FISH and NGS, such as the combination of venetoclax plus decitabine, and Sorafenib for patients with high FLT3-ITD allelic ratio. This study aims to improve induction therapy for non-elderly AML patients with adverse genetic risk features, reduce treatment-related complications, and improve overall survival. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04752527
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact suning chen, professor
Phone 8613814881746
Email chensuning@sina.com
Status Recruiting
Phase Phase 2
Start date February 20, 2021
Completion date December 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05133882 - A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML Phase 1/Phase 2
Active, not recruiting NCT05601726 - First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients Phase 1
Recruiting NCT06200441 - Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
Recruiting NCT04050280 - CLAG-GO for Patients With Persistent, Relapsed or Refractory AML Phase 2
Not yet recruiting NCT06252584 - Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients Phase 1
Recruiting NCT05988047 - Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia
Terminated NCT03951961 - Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Phase 2
Enrolling by invitation NCT03902665 - Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 Phase 2
Not yet recruiting NCT06285136 - Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult Phase 2/Phase 3
Recruiting NCT05127798 - RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.
Recruiting NCT05906914 - Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia Phase 2
Not yet recruiting NCT06199557 - A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients Phase 1/Phase 2
Recruiting NCT03766126 - Lentivirally Redirected CD123 Autologous T Cells in AML Phase 1
Recruiting NCT05674539 - Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome Phase 3
Enrolling by invitation NCT02985372 - Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia Phase 3
Recruiting NCT05703126 - Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML N/A
Recruiting NCT04240600 - Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay N/A
Terminated NCT04425655 - Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. Phase 2
Recruiting NCT04454580 - Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
Recruiting NCT05001828 - Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia Phase 1